We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+56.81%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$142M
AUM Growth
+$79.2M
Cap. Flow
+$33.4M
Cap. Flow %
23.56%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SYBX
Synlogic
SYBX
+$36.2M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
2 Communication Services 1.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.52B
$89M 62.83%
3,579,788
-150,000
-4% -$2.83M
SYBX
2
DELISTED
Synlogic
SYBX
$50.4M 35.63%
+176,798
New +$36.2M
SNAP icon
3
Snap
SNAP
$8.02B
$2.18M 1.54%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q3 2017 Portfolio in Review

As of Q3 2017, Atlas Venture Associates IX held 3 positions worth $142M, up 127% from $62.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX deployed $33.4M of net new capital in Q3 2017, opening 1 new position. Its largest new stake was Synlogic: 176,798 shares worth $50.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Intellia Therapeutics, an estimated $2.83M trimmed.

  • Atlas Venture Associates IX's largest Q3 2017 buy was Synlogic: 176,798 shares worth $50.4M.
  • Atlas Venture Associates IX's biggest Q3 2017 reduction was Intellia Therapeutics, cutting an estimated $2.83M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $142M portfolio in Q3 2017.
  • Atlas Venture Associates IX opened 1 new position and closed 0 in Q3 2017.
  • Atlas Venture Associates IX's portfolio value rose 127% quarter-over-quarter to $142M.

Based on Atlas Venture Associates IX's 13F filing for Q3 2017, filed 3 Nov 2017.